Cathepsin D Serum and Urine Concentration in Superficial and Invasive Transitional Bladder Cancer As Determined by Surface Plasmon Resonance Imaging

Overview

Journal Oncol Lett

Specialty Oncology

Date 2014 Aug 15

PMID 25120717

Citations 7

Authors

Ewa Gorodkiewicz

Tomasz Guszcz

Wieslawa Roszkowska-Jakimiec

Robert Kozlowski

Affiliations

Soon will be listed here.

Abstract

Determination of cathepsin D (Cat D) concentration in serum and urine may be useful in the diagnosis of bladder cancer. The present study included 54 healthy patients and 68 patients with bladder cancer, confirmed by transurethral resection or cystectomy. Cat D concentration was determined using a surface plasmon resonance imaging biosensor. Cat D concentration in the serum of bladder cancer patients was within the range of 1.3-5.59 ng/ml, while for healthy donors it was within the range of 0.28-0.52 ng/ml. In urine, the Cat D concentration of bladder cancer patients was within the range of 1.35-7.14 ng/ml, while for healthy donors it was within the range of 0.32-0.68 ng/ml. Cat D concentration may represent an efficient tumor marker, as its concentration in the serum and urine of transitional cell carcinoma patients is extremely high when compared with healthy subjects.

Citing Articles

A Comparison of Various Chips Used for the Manufacture of Biosensors Applied in Non-Fluidic Array SPRi, Based on the Example of Determination of Cathepsin D.

Falkowski P, Mrozek P, Miluski P, Lukaszewski Z, Gorodkiewicz E Biosensors (Basel). 2022; 12(1).

PMID: 35049649 PMC: 8773720. DOI: 10.3390/bios12010021.

Plasma aromatase as a sensitive and selective potential biomarker of bladder cancer and its role in tumorigenesis.

Guszcz T, Szymanska B, Kozlowski R, Lukaszewski Z, Laskowski P, Gorodkiewicz E Oncol Lett. 2020; 19(1):562-568.

PMID: 31897172 PMC: 6923837. DOI: 10.3892/ol.2019.11080.

Immunoproteasome in the blood plasma of children with acute appendicitis, and its correlation with proteasome and UCHL1 measured by SPR imaging biosensors.

Matuszczak E, Sankiewicz A, Debek W, Gorodkiewicz E, Milewski R, Hermanowicz A Clin Exp Immunol. 2017; 191(1):125-132.

PMID: 28940383 PMC: 5721234. DOI: 10.1111/cei.13056.

Peptide probes derived from pertuzumab by molecular dynamics modeling for HER2 positive tumor imaging.

Yang X, Wang Z, Xiang Z, Li D, Hu Z, Cui W PLoS Comput Biol. 2017; 13(4):e1005441.

PMID: 28406988 PMC: 5390981. DOI: 10.1371/journal.pcbi.1005441.

Methods for 20S Immunoproteasome and 20S Constitutive Proteasome Determination Based on SPRI Biosensors.

Sankiewicz A, Markowska A, Lukaszewski Z, Puzan B, Gorodkiewicz E Cell Mol Bioeng. 2017; 10(2):174-185.

PMID: 28356996 PMC: 5352758. DOI: 10.1007/s12195-017-0478-7.

References

Gorodkiewicz E, Regulska E, Wojtulewski K . Development of an SPR imaging biosensor for determination of cathepsin G in saliva and white blood cells. Mikrochim Acta. 2011; 173(3-4):407-413. PMC: 3092066. DOI: 10.1007/s00604-011-0569-4. View

Metaye T, Millet C, Kraimps J, Aubouin B, Barbier J, BEGON F . Estrogen receptors and cathepsin D in human thyroid tissue. Cancer. 1993; 72(6):1991-6. DOI: 10.1002/1097-0142(19930915)72:6<1991::aid-cncr2820720633>3.0.co;2-m. View

Szajda S, Darewicz B, Kudelski J, Chlabicz M, Domel T, Chabielska E . [Cancer procoagulant and cathepsin D activity in blood serum in patients with bladder cancer]. Pol Merkur Lekarski. 2005; 18(108):651-3. View

Craig Hall M, Chang S, Dalbagni G, Pruthi R, Seigne J, Skinner E . Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007; 178(6):2314-30. DOI: 10.1016/j.juro.2007.09.003. View

Tokyol C, Koken T, Demirbas M, Dilek F, Yorukoglu K, Mungan U . Expression of cathepsin D in bladder carcinoma: correlation with pathological features and serum cystatin C levels. Tumori. 2006; 92(3):230-5. DOI: 10.1177/030089160609200308. View

Lee H, Nedelkov D, Corn R . Surface plasmon resonance imaging measurements of antibody arrays for the multiplexed detection of low molecular weight protein biomarkers. Anal Chem. 2006; 78(18):6504-10. DOI: 10.1021/ac060881d. View

Barrett A . Cathepsin D. Purification of isoenzymes from human and chicken liver. Biochem J. 1970; 117(3):601-7. PMC: 1178965. DOI: 10.1042/bj1170601. View

Veneroni S, Daidone M, Di Fronzo G, Cappelletti V, Amadori D, Riccobon A . Quantitative immunohistochemical determination of cathepsin-D and its relation with other variables. Breast Cancer Res Treat. 1993; 26(1):7-13. DOI: 10.1007/BF00682695. View

Eissa S, Swellam M, Sadek M, Mourad M, El Ahmady O, Khalifa A . Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. J Urol. 2002; 168(2):465-9. View

10.

Gorodkiewicz E . Surface Plasmon Resonance Imaging sensor for cathepsin determination based on immobilized cystatin. Protein Pept Lett. 2009; 16(11):1379-85. DOI: 10.2174/092986609789353754. View

11.

Salman T, El-Ahmady O, El-Shafee M, Omar S, SALMAN I . Cathepsin-D and TNF-alpha in bladder cancer. Dis Markers. 1996; 12(4):253-9. DOI: 10.1155/1996/250191. View

12.

Herr H . Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol. 2001; 19(1):89-93. DOI: 10.1200/JCO.2001.19.1.89. View

13.

Faust P, Kornfeld S, Chirgwin J . Cloning and sequence analysis of cDNA for human cathepsin D. Proc Natl Acad Sci U S A. 1985; 82(15):4910-4. PMC: 390467. DOI: 10.1073/pnas.82.15.4910. View

14.

Lotan Y, Shariat S, Schmitz-Drager B, Sanchez-Carbayo M, Jankevicius F, Racioppi M . Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol. 2010; 28(4):441-8. DOI: 10.1016/j.urolonc.2009.11.004. View

15.

Kotaska K, Dusek P, Prusa R, Vesely S, Babjuk M . Urine and serum cathepsin B concentrations in the transitional cell carcinoma of the bladder. J Clin Lab Anal. 2012; 26(2):61-5. PMC: 6807346. DOI: 10.1002/jcla.21483. View

16.

Warwas M, Taurowska E . [Cathepsin D in diagnosis of neoplastic diseases]. Postepy Hig Med Dosw. 1993; 47(4):277-88. View

17.

Burger M, Catto J, Dalbagni G, Grossman H, Herr H, Karakiewicz P . Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2012; 63(2):234-41. DOI: 10.1016/j.eururo.2012.07.033. View

18.

Tetu B, Brisson J, Cote C, Brisson S, Potvin D, Roberge N . Prognostic significance of cathepsin-D expression in node-positive breast carcinoma: an immunohistochemical study. Int J Cancer. 1993; 55(3):429-35. DOI: 10.1002/ijc.2910550318. View

19.

Gorodkiewicz E, Ostrowska H, Sankiewicz A . SPR imaging biosensor for the 20S proteasome: sensor development and application to measurement of proteasomes in human blood plasma. Mikrochim Acta. 2011; 175(1-2):177-184. PMC: 3179842. DOI: 10.1007/s00604-011-0656-6. View

20.

Gorodkiewicz E, Regulska E . SPR imaging biosensor for aspartyl cathepsins: sensor development and application for biological material. Protein Pept Lett. 2010; 17(9):1148-54. DOI: 10.2174/092986610791760450. View